Literature DB >> 29609758

Is Lipoprotein(a) Ready for Prime-Time Use in the Clinic?

Katrina L Ellis1, Gerald F Watts2.   

Abstract

Lipoprotein (a) is a low-density lipoprotein-like particle covalently bound to a glycoprotein called apolipoprotein(a) that is under potent genetic control. Plasma levels of lipoprotein (a) vary by up to 1000-fold among individuals, with 1 in 4 having levels that increase the risk of atherosclerotic cardiovascular disease. New evidence supports a causal role for lipoprotein (a) in atherosclerotic cardiovascular disease and aortic valve stenosis. Individuals with elevated lipoprotein (a) have a high life-time burden of atherosclerotic cardiovascular disease. This notion is important for coronary prevention. But is lipoprotein (a) ready for prime-time use in coronary prevention clinics?
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atherosclerotic cardiovascular disease; Lipoprotein(a); Models of care; Pharmacotherapy; Risk assessment

Mesh：

Substances：

Year:  2018        PMID： 29609758     DOI： 10.1016/j.ccl.2017.12.010

Source DB:  PubMed          Journal:  Cardiol Clin        ISSN： 0733-8651            Impact factor:   2.213


  6 in total

1.  A genome-wide association study on lipoprotein (a) levels and coronary artery disease severity in a Chinese population.

Authors:  Yibin Liu; Hongkun Ma; Qian Zhu; Bin Zhang; Hong Yan; Hanping Li; Jinxiu Meng; Weihua Lai; Liwen Li; Danqing Yu; Shilong Zhong
Journal:  J Lipid Res       Date:  2019-06-11       Impact factor: 5.922

2.  Circulating PCSK9 Linked to Dyslipidemia in Lebanese Schoolchildren.

Authors:  Yara Azar; Marie-Hélène Gannagé-Yared; Elie Naous; Carine Ayoub; Yara Abou Khalil; Elise Chahine; Sandy Elbitar; Youmna Ghaleb; Catherine Boileau; Mathilde Varret; Petra El Khoury; Marianne Abifadel
Journal:  Metabolites       Date:  2022-05-31

Review 3.  Molecular, Population, and Clinical Aspects of Lipoprotein(a): A Bridge Too Far?

Authors:  Natalie C Ward; Karam M Kostner; David R Sullivan; Paul Nestel; Gerald F Watts
Journal:  J Clin Med       Date:  2019-11-27       Impact factor: 4.241

4.  Lipid Parameters and Proprotein Convertase Subtilisin/Kexin Type 9 in Healthy Lebanese Adults.

Authors:  Marie-Hélène Gannagé-Yared; Elie Naous; Anis Al Achkar; Wadih Issa; Ghassan Sleilaty; Vanda Barakett-Hamade; Marianne Abifadel
Journal:  Metabolites       Date:  2022-07-26

Review 5.  Lipoprotein(a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein(a) Molecule.

Authors:  Motasim M Jawi; Jiri Frohlich; Sammy Y Chan
Journal:  J Lipids       Date:  2020-02-01

6.  Prevalence and status of Lipoprotein (a) among Lebanese school children.

Authors:  Marie-Hélène Gannagé-Yared; Christina Lahoud; Nada Younes; Rima Chedid; Ghassan Sleilaty
Journal:  Sci Rep       Date:  2020-11-26       Impact factor: 4.379
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.